Based on the expression levels of BRD4 and PD-L1, AML patients were divided into three groups: group I, BRD4lowPD-L1low; group II, BRD4highPD-L1low or BRD4lowPD-L1high; and group III, BRD4highPD-L1high. This evidence concerns the gene CD274 and acute myeloid leukemia.